PuSH - Publication Server of Helmholtz Zentrum München

Zimmermann, G.S. ; von Wulffen, W. ; Huppmann, P. ; Meis, T. ; Ihle, F. ; Geiseler, J.* ; Leuchte, H.H.* ; Tufman, A. ; Behr, J. ; Neurohr, C.

Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors.

Respirology 19, 700-706 (2014)
DOI
Open Access Green as soon as Postprint is submitted to ZB.
Background and objective Interstitial lung diseases (ILD) are often associated with pulmonary hypertension (PH). This study aimed to evaluate the therapeutic benefit of phosphodiesterase-5 (PDE-5) inhibitors in pulmonary hypertension secondary to ILD. Methods Patients with ILD and PH were treated with sildenafil or tadalafil. Right heart catheterization was performed before and after a minimum of 3-month treatment. In addition, lung function, 6-min walk distance (6MWD) and plasma brain natriuretic peptide (BNP) concentration were assessed. Results Ten ILD patients (three female, mean age 64.4 +/- 9.0 years, six with idiopathic pulmonary fibrosis (IPF), four with hypersensitivity pneumonitis, (HP)) with significant precapillary PH (mean pulmonary artery pressure (PAPm)25mmHg, pulmonary vascular resistance (PVR)>280 dyn*s*cm-5; pulmonary artery wedge pressure (PAWPm)15mmHg) were treated with either sildenafil (n=5) or tadalafil (n=5). Pulmonary haemodynamics were severely impaired at baseline (PAPm 42.9 +/- 5.4mmHg; cardiac index (CI) 2.7 +/- 0.6 L/min/m2; PVR 519 +/- 131 dynxsecxcm-5). After mean follow-up of 6.9 +/- 5.8 months an increase in CI (2.9 +/- 0.7 L/min/m2, P=0.04) and a decrease in PVR (403 +/- 190 dynxsecxcm-5, P=0.03) were observed. 6MWD and BNP did not change significantly. Conclusions Our data suggest that treatment with PDE-5 inhibitors improves pulmonary haemodynamic patients with PH secondary to ILD.
Altmetric
Additional Metrics?
[➜Log in]
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Keywords Idiopathic Pulmonary Fibrosis ; Interstitial Lung Disease ; Phosphodiesterase 5 Inhibitor ; Pulmonary Fibrosis ; Pulmonary Hypertension; Brain Natriuretic Peptide; Arterial-hypertension; Controlled-trial; Fibrosis; Sildenafil; Statement; Therapy; Guidelines; Expression; Exercise
ISSN (print) / ISBN 1323-7799
e-ISSN 1440-1843
Journal Respirology
Quellenangaben Volume: 19, Issue: 5, Pages: 700-706 Article Number: , Supplement: ,
Publisher Wiley
Publishing Place Hoboken
Reviewing status Peer reviewed
Institute(s) Institute of Lung Health and Immunity (LHI)